U.S. DIABETIC NEUROPATHY MARKET ANALYSIS

U.S. Diabetic Neuropathy Market, by Drug (Tricyclic Antidepressants (Amitriptyline, Nortyptyline, Imipramine, Desipramine), SSRI (Paroxetine, Citalopram), Anticonvulsants (Gabapentin, Pregabalin, Carbamazepine), Opioids (Tramadol, Tapentadol, Oksikodon), SNRIs (Duloxetine), Other Drugs (Capsaicin, Lidocaine, Botilinum Toxin)) by Type (Peripheral Neuropathy, Proximal Neuropathy, Autonomic Neuropathy, Focal Neuropathy), by Route of Administration (Oral, Topical, Injection (Intramuscular)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022
Code : CMI5356
Pages :160
Formats :
Excel and PDF
Industry : Pharmaceutical

U.S. Diabetic Neuropathy MarketSize and Trends

The U.S. diabetic neuropathy market is estimated to be valued at US$ 1,759.4 million in 2022 and is expected to exhibit a CAGR of 5.2% during the forecast period (2022-2030).

Figure 1. U.S. Diabetic Neuropathy Share (%), by Type, 2022

U.S. Diabetic Neuropathy Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the U.S. diabetic neuropathy market due to the increasing risk of peripheral neuropathy from COVID-19. For instance, according to the data published in March 2022, by Washington University School of Medicine, COVID-19 patients are extremely at higher risk of experiencing symptoms of peripheral neuropathy, such as pain, numbness and tingling in the hands and feet, which, in turn, increased the sales of neuropathic treatment drugs, thus positively impacting the global diabetic neuropathy market growth.

U.S. Diabetic Neuropathy Market: Key Developments

U.S. Diabetic Neuropathy Market Report Snapshots